Prison needle exchange programs can reduce infections while saving money

Publicly released:
Australia; International; VIC
Photo by Rapha Wilde on Unsplash
Photo by Rapha Wilde on Unsplash

Spending a dollar on a prison needle exchange program can save $2 in infection treatment costs, according to Australian researchers who modelled the effectiveness of a Canadian program. The program allows inmates who use drugs to swap their needles for clean ones in an attempt to reduce the rate of injection-related infections such as hepatitis C. The researchers calculate if the Canadian needle exchange program was expanded to cover 50% of federal inmates who inject drugs, 15% of new hepatitis C cases and 8% of injection-related infections could be prevented. The researchers say this study shows the benefit programs like these likely have globally.

Media release

From: Canadian Medical Association Journal

Federal needle exchange programs are cost-effective to reduce health care costs, blood-borne infections

New research suggests that every dollar spent in Prison Needle Exchange Programs (PNEPs) in Canadian federal prisons will save $2 in infection treatment costs, making the case for further investment in these programs. The research is published in CMAJ (Canadian Medical Association Journal).

“Needle exchange programs are evidence-based strategies that prevent transmission of blood-borne viruses, reduce injection-related infections, improve access to medical care, and facilitate entry into substance dependence programs for people who inject drugs,” writes Dr. Farah Houdroge, Disease Elimination Program, Burnet Institute, Melbourne, Australia, with coauthors.

The World Health Organization has set a target of reducing hepatitis C infections to fewer than 2 per 100 people who inject drugs per year as part of an elimination strategy for hepatitis C. In 2024, Canada unveiled its 2024–2030 Sexually Transmitted and Blood-Borne Infection Action Plan that emphasized support for harm reduction programs and expanding the PNEP.

Researchers from Canada and Australia sought to assess the return on investment for Canada’s PNEP, and the potential impact of scaling it up, as part of efforts to eliminate blood-borne infections in prisons. Using a modelling study, they found that expanding the program to 50% of people in all federal prisons who inject drugs from 2025 to 2030 would prevent 15% of new hepatitis C cases and 8% of injection-related infections compared with the status quo.

“This study adds to the growing body of evidence supporting PNEPs as effective harm reduction strategies that are also cost saving. Given that they show both health and economic benefits, PNEPs should be a priority not just in Canada, but globally,” the authors conclude.

In a related commentary, authors argue that more comprehensive interventions to make substance use in correctional institutions safer, and specifically reduce related risks of acute death, are needed. “Prison-based programs aimed at mitigating the health harms of substance use by correctional inmate populations should be carefully evaluated as part of their implementation, as has been done in the related research with specific respect to needle exchange programs. Without systematic expansion of and increased access to such programs, prisoners in Canada will remain at unnecessarily high risk of ill health and death from the adverse consequences of substance use,” the authors conclude.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research Canadian Medical Association Journal, Web page The URL will go live after the embargo ends
Editorial / Opinion Canadian Medical Association Journal, Web page The URL will go live after the embargo ends
Journal/
conference:
Canadian Medical Association Journal
Research:Paper
Organisation/s: Burnet Institute
Funder: Nadine Kronfli reports receiving research funding from the Canadian Institutes of Health and HIV/AIDS Research Initiative (grant numbers 190374 and 185725); Dr. Kronfli is also supported by a career award from the Fonds de Recherche Québec — Santé (FRQ-S; Junior 2). Mark Stoové reports receiving a Viiv Healthcare Medical Education Grant. No other competing interests were declared.
Media Contact/s
Contact details are only visible to registered journalists.